The Netherlands Cancer Institute (NKI), one of the world’s top 10 comprehensive cancer centres, is using artificial intelligence (AI) for lung nodule management. The AI solution, Veye Lung Nodules, is provided by MedTech scaleup Aidence.
Veye Lung Nodules is a CE certified second or concurrent reader used in routine practice and lung cancer screening across Europe. At NKI, it will analyse over 15,000 chest CT scans per year, and the additional prior scans for approximately 80% of studies.
Mark-Jan Harte, Aidence Co-founder and CEO, said:
“The Netherlands Cancer Institute and Aidence share the bold ambition to reduce the global burden of cancer. Our partnership reflects the important role of innovation, particularly AI, in improving cancer detection, diagnostics and treatment. We are proud to work with this acclaimed oncology site.”
Laurens Topff, Radiologist and Researcher at NKI, on selecting Aidence’s application:
“At the Netherlands Cancer Institute, we’re continuously striving to improve diagnosis and treatment monitoring in cancer patients. AI-based tools can augment the radiologist’s expertise in image interpretation. We have thus implemented Veye Lung Nodules in our daily clinical workflow.
The software is assisting us with the detection and follow-up of potential lung metastases on CT. It provides objective volumetric analysis of lung nodules and can assess changes over time. This helps us to be more accurate and efficient in reporting follow-up scans.
With this collaboration, we combine our medical expertise in cancer imaging with the experience of Aidence in the development and deployment of AI applications for clinical use.”
NKI and Aidence are further working together in the development of new AI-based medical devices. NKI is running the validation study of Aidence’s covid-19 model and supporting the extension of the lung nodule solution to treatment response assessment in lung cancer care.
About The Netherlands Cancer Institute
The Netherlands Cancer Institute comprises an internationally acclaimed research institute as well as a dedicated cancer clinic. This combination ensures rapid translation of basic research into clinical applications: today’s research for tomorrow’s cure.
